<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574688</url>
  </required_header>
  <id_info>
    <org_study_id>2016894_PILOT</org_study_id>
    <nct_id>NCT03574688</nct_id>
  </id_info>
  <brief_title>The Hydration to Optimize Metabolism (H2O Metabolism) Pilot Study</brief_title>
  <acronym>H2OMetaboPilot</acronym>
  <official_title>The Hydration to Optimize Metabolism (H2O Metabolism) Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danone Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates increased hydration (1.5 L of water daily during 6 weeks) on top of&#xD;
      habitual water intake in the lowering of the vasopressin marker copeptin and in the lowering&#xD;
      of plasma glucose concentration in adults with signs of low water intake at recruitment&#xD;
      (elevated levels of copeptin, high urine osmolality, low urine volume).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High plasma concentration of vasopressin (i.e. antidiuretic hormone) is a novel and&#xD;
      independent risk factor for type 2 diabetes, the metabolic syndrome, cardiovascular disease&#xD;
      and premature death. The main physiological role of vasopressin is to maintain constant&#xD;
      plasma osmolality. Previous studies in rats and a Mendelian randomization study in humans&#xD;
      suggest causality between elevated vasopressin concentration and elevated plasma glucose&#xD;
      concentration. As vasopressin can be suppressed by increasing water intake, the investigators&#xD;
      hypothesize that water supplementation in individuals with high vasopressin can lower plasma&#xD;
      glucose and prevent diabetes.&#xD;
&#xD;
      The aim of this pilot study is to test if six weeks of water supplementation of 1.5 Liters of&#xD;
      extra water per day in low-drinkers with high copeptin can significantly alter hydration&#xD;
      markers in general and reduce plasma copeptin in particular. Furthermore, the investigators&#xD;
      also aim at investigating whether this 6-week water intervention can significantly reduce&#xD;
      fasting plasma glucose concentration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Actual">July 25, 2017</completion_date>
  <primary_completion_date type="Actual">July 25, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants of this pilot intervention study had the intervention of 1.5 Liters of increased daily water intake per day during 6 weeks.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting plasma copeptin concentration (pmol/L)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of fasting plasma copeptin between baseline and after 6 weeks of increased water intake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour urine osmolality (mosm/kg H2O)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of 24 hour urine osmolality between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urine volume (L/24h)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of 24 hour urine volume between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinking water (L/day)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of intake of tap and bottled water between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total water (L/day)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of total water intake between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose concentration (mmol/L)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change of Fasting plasma glucose concentration between baseline and after 6 weeks of increased water intake.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Low Water Intake</condition>
  <condition>High Vasopressin</condition>
  <arm_group>
    <arm_group_label>Water intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.</description>
    <arm_group_label>Water intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
          -  Age 20-75 years&#xD;
&#xD;
          -  High plasma concentration of copeptin of &gt;6.1 pmol/L in women and &gt; 10.7 pmol/L in men&#xD;
&#xD;
          -  24-hour urine osmolality &gt; 600 milliosmol (mosm) /kg water.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  24-hour urine volume &gt;1.5 L&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Plasma sodium &lt;135 mmol/L&#xD;
&#xD;
          -  Use of diuretics, lithium or SSRI drugs&#xD;
&#xD;
          -  Chronic kidney disease (estimated glomerular filtration rate &lt; 30mL/min)&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Type 1 diabetes or type 2 diabetes treated with insulin&#xD;
&#xD;
          -  Vulnerable subjects (subjects with legal guardian, with loss of personal liberty)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olle Melander, M.D., Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KFE, Skåne University Hospital in Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>June 30, 2018</last_update_submitted>
  <last_update_submitted_qc>June 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region Skane</investigator_affiliation>
    <investigator_full_name>Olle Melander</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hydration</keyword>
  <keyword>Water</keyword>
  <keyword>Vasopressin</keyword>
  <keyword>Copeptin</keyword>
  <keyword>Glucose</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03574688/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

